Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-Finding Study in Comparison With Open Label Enoxaparin.

Trial Profile

Direct Factor Xa Inhibitor YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement.---A Double Blind, Parallel, Dose-Finding Study in Comparison With Open Label Enoxaparin.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Darexaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ONYX-2
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 19 Jan 2010 Actual patient number changed 1139 to 1141 from reported by ClinicalTrials.gov.
    • 14 Jul 2009 Additional locations identified as reported by ClinicalTrials.gov.
    • 11 Oct 2007 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top